Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating pazopanib and everolimus versus standard sequential pazopanib then everolimus in advanced clear cell renal cell carcinoma
NL-OMON39600Phase 2Active, not recruiting
- Sponsor
- WIN-O
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pazopanib and everolimus in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by WIN-O. Primary endpoint: Progression-free survival. Started Sep 2012; status: active, not recruiting.
02
Drugs
pazopanibeverolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON39600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39600.